Advanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
References
Sources used in this report
SEC APISEC company tickers exchange dataset2026-05-14 · Ticker, exchange, company name, and CIK confirmation.SEC APISEC submissions JSON2026-05-14 · Issuer identity, SIC, fiscal year end, address, and filing sequence.SEC APISEC companyfacts JSON2026-05-14 · XBRL cross-checks for filed financial facts.SEC annual filingFY2025 Form 10-K2025-10-08 · Historical business, product pipeline, no-revenue disclosure, employees, FY2025 financials, cash flow, ownership, related-party funding, and risks.SEC quarterly filingQ2 FY2026 Form 10-Q2026-02-13 · December 2025 balance sheet, six-month results, disposal gain, operating cash flow, related-party balances, and subsidiary structure.SEC current reportDecember 2025 Form 8-K2025-12-30 · Hong Kong subsidiary disposal, intellectual property transfer, and stated Taiwan clinical-trial realignment.SEC current reportSeptember 2025 Form 8-K2025-09-19 · A+PerfusC launch and product-development status.SEC current reportFebruary 2026 Form 8-K2026-02-26 · 1-for-20 reverse split and Nasdaq minimum-bid compliance objective.SEC current reportApril 2026 Form 8-K on operating loan2026-04-14 · $600,000 unsecured loan, 10% annual interest, six-month term, and operating use of proceeds.SEC current reportMay 2026 Form 8-K on Acellent acquisition and AI pivot2026-05-01 · Acellent acquisition, 270,000-share consideration, AI pivot, leadership transition, and Xiaomin Chen appointment.SEC information statementJanuary 2026 definitive information statement2026-01-23 · Reverse-split approval framework and governance process.U.S. government regulator contextFDA in vitro diagnostics overview2026-05-14 · Category context for in vitro diagnostics and precision-medicine tests.U.S. government oncology contextNCI tumor markers fact sheet2026-05-14 · Context for tumor markers and liquid biopsy tests.